Abcellera Biologics Inc revenue growth has been varied year-over-year.

What is ABCL's revenue growth rate?

Historical revenue data is available for Abcellera Biologics Inc to analyze growth trends.

How fast is ABCL earnings growing?

Earnings growth data is available for Abcellera Biologics Inc analysis.

What is ABCL's profit margin?

Profit margin data is available for Abcellera Biologics Inc.

ABCL Revenue & Earnings Growth Analysis 2026 - Is Abcellera Biologics Inc Growing?

Growth Summary

Abcellera Biologics Inc (ABCL) has experienced challenges in growth. The company operates in the Healthcare sector, specifically in the Biotechnology industry.

Over the past 4 years, Abcellera Biologics Inc has achieved a revenue compound annual growth rate (CAGR) of -40.7%.

Latest Revenue

$28.83M

Net Income

$-162857000.00

5-Year Revenue CAGR

-40.7%

4 years of data

Net Margin

N/A

Latest period

Revenue Growth Over Time

Historical revenue and profitability trends for Abcellera Biologics Inc

The chart above illustrates Abcellera Biologics Inc's revenue trajectory over the past 4 years. The revenue pattern shows the challenges the company has faced in recent periods.

Year-over-Year Growth Rates

Annual percentage change in revenue and earnings

Growth rates provide insight into the momentum of Abcellera Biologics Inc's business.

Profit Margin Trends

How efficiently Abcellera Biologics Inc converts revenue into profit

Understanding Profit Margins

Profit margins reveal how much of each dollar of revenue Abcellera Biologics Inc retains at different stages:

Gross Margin (N/A%): What remains after direct production costs
Operating Margin (N/A%): Profit from core operations before interest and taxes
Net Margin (N/A%): Final profit after all expenses

Future Growth Outlook

Analyst estimates and forward-looking indicators

EPS Estimate 2026

$-0.65

Current: $-0.55

EPS Estimate 2027

$-0.69

5.7% expected growth

Price Target

$9.83

Analyst consensus

What Analysts Are Saying

Wall Street analysts project Abcellera Biologics Inc to continue focusing on sustainable operations. The consensus analyst rating is 4.5556 based on 9 analysts.

Growth Analysis Conclusion

Based on our comprehensive analysis, Abcellera Biologics Inc (ABCL) demonstrates declining growth characteristics.

Key Takeaways:

Revenue Growth:, -40.7% CAGR over 4 years
Profitability: shows the company is investing in growth over short-term profits
Efficiency:

Investment Considerations

This growth analysis provides a comprehensive view of Abcellera Biologics Inc's historical performance and future outlook. Investors should consider these growth metrics alongside valuation, competitive positioning, and broader market conditions when making investment decisions. Past performance does not guarantee future results.